UBC BIMZELX superior to AbbVie SKYRIZI® in first head-to-head study in active psoriatic arthritis

 

• Primary endpoint showing superiority met: Bimekizumab achieved statistically significant superiority over risankizumab in reducing disease activity, as measured by the stringent ACR50 endpoint, at Week 16 in adults living with active psoriatic arthritis
• Landmark psoriatic arthritis (PsA) study: Bimekizumab is the first licensed biologic therapy to demonstrate superiority in psoriatic arthritis over an IL-23 inhibitor
• Fourth bimekizumab study showing superiority: BE BOLD is the fourth head-to-head study demonstrating superiority in the bimekizumab clinical trial program across psoriatic disease, and the first conducted in PsA

https://www.prnewswire.com/news-releases/bimzelxbimekizumab-superior-to-skyrizi-risankizumab-in-be-bold-first-head-to-head-study-in-active-psoriatic-arthritis-psa-to-demonstrate-superiority-in-acr50-302710228.html